RecruitingPhase 3NCT06491108

Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Vardenafil Versus Tadalafil Versus Tamsulosin in Patients With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Prospective Randomized Study.


Sponsor

Tanta University

Enrollment

150 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The main objective of this prospective randomized controlled study is to compare safety and efficacy of Vardenafil versus Tadalafil versus Tamsulosin in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS.


Eligibility

Sex: MALEMin Age: 40 YearsMax Age: 70 Years

Inclusion Criteria3

  • Sexually active patients .
  • ModerateBPH related LUTS ( bengin prostatic hyperplasia related lower urinary tract symtoms ) i.e: (international prostatic symptom score 8 to 19 : the higher score is the worse symptoms ).
  • Patients accepted medical treatment and completed 12 weeks on medical treatment and strict follow up .

Exclusion Criteria8

  • Indication for combined therapy as prostate size over 40 gm .
  • Gross hematuria.
  • Refractory urine retention .
  • Bilateral hydro-ureteronephrosis or renal insufficiency secondary to bengin prostatic hyperplasia.
  • Bladder diverticula or calculi .
  • History of bladder or prostate cancer.
  • Unwilling patients to medical therapy.
  • History of pelvic surgery or urethral stricture.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVardenafil 5 Mg Oral Tablet

Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )


Locations(1)

Faculity of medicine - Tanta university

Tanta, Gharbia Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06491108